Edition:
United States

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

13.65USD
18 Aug 2017
Change (% chg)

$0.05 (+0.37%)
Prev Close
$13.60
Open
$13.50
Day's High
$13.68
Day's Low
$13.50
Volume
74,626
Avg. Vol
79,466
52-wk High
$19.80
52-wk Low
$10.77

VIVO.OQ

Chart for VIVO.OQ

About

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain... (more)

Overall

Beta: 0.86
Market Cap(Mil.): $573.96
Shares Outstanding(Mil.): 42.20
Dividend: 0.12
Yield (%): 3.68

Financials

  VIVO.OQ Industry Sector
P/E (TTM): 27.12 30.22 32.70
EPS (TTM): 0.50 -- --
ROI: 9.27 13.77 14.88
ROE: 12.68 16.61 16.12

BRIEF-Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line

* Meridian Bioscience Inc- ‍Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B​ Source text for Eikon: Further company coverage:

Aug 08 2017

BRIEF-Meridian Bioscience Q3 gaap earnings per share $0.01

* Meridian Bioscience reports third fiscal quarter 2017 operating results, including non-cash goodwill impairment charge, declares regular cash dividend, and reaffirms fiscal 2017 guidance excluding the effect of goodwill impairment charge

Jul 27 2017

BRIEF-Co-Diagnostics Inc announces joint venture in India

* Co-Diagnostics Inc - once deal completed, cosara will have exclusive indian manufacturing rights for co-diagnostics products

Jul 25 2017

FDA raises concerns about Meridian's plant that makes lead tests

The U.S. health regulator on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures lead testing devices, nearly two months after the regulator warned that the tests may underestimate lead levels in blood.

Jul 13 2017

UPDATE 2-FDA raises concerns about Meridian's plant that makes lead tests

July 13 The U.S. health regulator on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures lead testing devices, nearly two months after the regulator warned that the tests may underestimate lead levels in blood.

Jul 13 2017

BRIEF-Meridian Bioscience comments on FDA statement concerning inspection of Magellan diagnostics

* Meridian Bioscience Inc- ‍Consistent with FDA policy, Magellan will promptly submit responses to form FDA-483 for agency's consideration​

Jul 13 2017

FDA raises fresh concerns over Meridian's lead testing device

July 13 The U.S. Food and Drug Administration on Thursday raised concerns about Meridian Bioscience Inc's facility that manufactures its testing device nearly two months after the regulator warned the tests underestimate lead levels in blood.

Jul 13 2017

BRIEF-Co-Diagnostics sees IPO of 1.3 mln common shares to be priced between $6.35-$6.75/Share

* Co-Diagnostics Inc sees IPO of 1.3 million shares of common stock to be priced between $6.35 and $6.75 per share - sec filing Source text : http://bit.ly/2tb5xtJ Further company coverage:

Jun 26 2017

BRIEF-Meridian Bioscience comments on recent FDA posting related to Magellan Diagnostics

* Meridian Bioscience comments on recent fda posting related to Magellan Diagnostics

Jun 06 2017

BRIEF-Meridian Bioscience comments on FDA matter involving its subsidiary

* Meridian Bioscience comments on FDA matter involving its subsidiary, Magellan Diagnostics

May 17 2017

Competitors

Earnings vs. Estimates